Comparison
CJC-1295 vs Sermorelin
Short-acting versus long-acting GHRH analogs
The key difference
Both mimic GHRH. Sermorelin is short-acting; CJC-1295 (with DAC) binds albumin in the blood so it lasts far longer.
| CJC-1295 | Sermorelin | |
|---|---|---|
| Class | Long-acting GHRH analog | GHRH analog |
| Evidence | Early human research | Human clinical trials |
| Status | Not FDA-approved. | Not currently marketed as an FDA-approved product. |
| Also known as | — | — |
| Researched for | Muscle & body composition, Sleep | Muscle & body composition, Sleep, Longevity |
| Evidence strength | Early human research | Human clinical trials |
What else differs
- Sermorelin has an older history as an approved medicine; CJC-1295 never completed development.
- Longer action changes the pattern of growth hormone release, which researchers consider important.
Bottom line
Similar target, very different duration, and a different regulatory history.
Read the research
CJC-1295 on PubMed →
Sermorelin on PubMed →
Educational content, not medical advice. This page does not recommend or dose any substance. Compounds that are not FDA-approved have not been established as safe or effective in people.